J&J eyes one billion doses of potential COVID-19 shot in 2021, weighs challenge trials

Malaysia News News

J&J eyes one billion doses of potential COVID-19 shot in 2021, weighs challenge trials
Malaysia Latest News,Malaysia Headlines
  • 📰 Reuters
  • ⏱ Reading Time:
  • 20 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 97%

Johnson & Johnson could produce 1 billion doses of its potential COVID-19 vaccine next year if it proves successful and would consider injecting healthy volunteers with the novel coronavirus if there are not enough patients for final trials, a company executive said.

) could produce 1 billion doses of its potential COVID-19 vaccine next year if it proves successful and would consider injecting healthy volunteers with the novel coronavirus if there are not enough patients for final trials, a company executive said.

Earlier on Tuesday, President Vladimir Putin said Russia had become the first country to grant regulatory approval to a COVID-19 vaccine after less than two months of human testing, and before large-scale trials had been conducted. That is why J&J is likely to conduct those trials in the United States and Latin America, the world’s regions currently with the highest number of cases.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Reuters /  🏆 2. in US

Malaysia Latest News, Malaysia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

China's Sinopharm starts Phase III trial of COVID-19 vaccine in BahrainChina's Sinopharm starts Phase III trial of COVID-19 vaccine in BahrainChinese state-owned pharmaceutical company Sinopharm has begun Phase III clinical trials of a COVID-19 vaccine in Bahrain, after launching similar trials in the United Arab Emirates last month, Bahrain's health ministry said on Monday.
Read more »

Sinovac launches late-stage trial for potential COVID-19 vaccine in IndonesiaSinovac launches late-stage trial for potential COVID-19 vaccine in IndonesiaChina's Sinovac Biotech Ltd launched on Tuesday a late-stage human trial involving as many as 1,620 patients in Indonesia for a COVID-19 vaccine candidate that it is developing with Indonesian state-owned peer Bio Farma.
Read more »

Sinovac launches Phase 3 trial for COVID-19 vaccine in Indonesia, reports Phase 2 detailsSinovac launches Phase 3 trial for COVID-19 vaccine in Indonesia, reports Phase 2 detailsChina's Sinovac Biotech Ltd launched a late-stage human trial on Tuesday that will involve as many as 1,620 patients in Indonesia for a COVID-19 vaccine candidate that it is developing with Indonesian state-owned peer Bio Farma.
Read more »

COVID-19: Our ExperienceCOVID-19: Our ExperienceWe now have over 5 million cases of COVID-19 in the U.S. -- but that number is more than just a grim statistic. Each one of those “cases” is a real person, with a unique experience. What 12 people who've been impacted by the virus want you to know:
Read more »



Render Time: 2025-03-04 07:39:02